Melasma

Clinical guidelines for managing chronic facial hyperpigmentation, identifying hormonal triggers, and reviewing tyrosinase inhibitor therapies.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Melasma is a common, acquired hyperpigmentation disorder characterized by symmetric brown or gray-brown patches on sun-exposed areas of the face.

πŸ” Melasma Depth & Wood's Lamp Examination

To determine the clinical prognosis and select appropriate treatments, dermatologists classify melasma based on the depth of melanin pigment using a Wood's lamp (black light) examination:

πŸ’Š Topical Tyrosinase Inhibitors

Topical therapy is the cornerstone of melasma management, designed to suppress melanin synthesis pathways.

Standard Topicals

🌿 Oral & Light-Shielding Therapies

For refractory or severe cases, advanced systemic agents and physical solar blockers provide crucial support.

πŸ“Š Disease Severity & The MASI Score

Dermatologists evaluate the severity of melasma using the **Melasma Area and Severity Index (MASI)**. The score ranges from 0 to 48, calculated by dividing the face into four regions (forehead, right malar, left malar, and chin):

πŸ”¬ Active Clinical Trials

Clinical trials are currently investigating oral TXA safety, novel non-hydroquinone topical molecules, and picosecond laser parameter protocols.

NCT06922221: Oral Tranexamic Acid vs Triple Combination Cream

Comparing the efficacy and recurrence rates of oral Tranexamic Acid against topical triple combination cream.

Key Inclusion: Moderate-to-severe bilateral facial melasma, duration ≥ 1 year, and MASI score ≥ 10 at screening.
NCT07049911: Novel Selective Topical Tyrosinase Inhibitor

Testing a novel selective topical tyrosinase inhibitor designed for long-term daily maintenance without local irritation.

Key Inclusion: Mild-to-moderate epidermal facial melasma, willing to undergo biopsy at baseline, and no topical hydroquinone or retinoid use for ≥ 2 months.
NCT07115200: Picosecond Lasers Combined with Topical Cysteamine

Evaluating the safety and clearance speed of picosecond lasers combined with topical cysteamine cream.

Key Inclusion: Mixed or dermal melasma confirmed by Wood's lamp, Fitzpatrick skin types III to V, and no history of post-inflammatory hyperpigmentation.
Important: Check out the full list of actively recruiting trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Melasma, follow these steps to manage pigmentation:

  1. Switch to a Tinted Mineral Sunscreen: Ensure your daily sunscreen contains iron oxides (look for "tinted" zinc oxide sunscreens) to protect against both UV and visible blue light.
  2. Review Hormone Medications: Discuss with your doctor if oral contraceptives or hormone therapies are contributing to the pigmentation and if non-hormonal alternatives are suitable.
  3. Avoid Skin Irritation: Harsh scrubs, waxing, or irritating skincare products can trigger post-inflammatory hyperpigmentation, worsening melasma. Use only gentle cleansers.
  4. Plan a Rotational Routine: If using hydroquinone-based creams, follow a strict schedule (e.g., 3 months on, 3 months off) under dermatological supervision to ensure safety.

❓ Patient FAQ

Q: Does melasma go away after pregnancy?
A: In many women, melasma that develops during pregnancy resolves or fades significantly within several months after delivery, although it can recur in subsequent pregnancies or with contraceptive use.

Q: Can computers or phone screens make my melasma worse?
A: Yes. Digital screens emit high-energy visible (blue) light, which has been shown to stimulate melanocytes and worsen pigmentation in individuals with darker skin types. Wearing tinted sunscreens containing iron oxides helps protect against digital light.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email